The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials
Open accessAbstract
BACKGROUND: It is unknown whether eradication of Helicobacter pylori infection prevents development of gastric adenocarcinoma. To determine whether screening and treatment trials are warranted, we conducted a cost-effectiveness analysis to estimate the costs and benefits associated with screening for H pylori at age 50 and treating those individuals infected with antibiotics. METHODS: We compared two interventions: (1) screen for H pylori and treat those with a positive test, and (2) do not screen and do not treat. Estimates of risks and costs were obtained by review of published reports. Since the efficacy of H pylori therapy in cancer prevention is unknown, we did sensitivity analyses, varying this estimate widely. In our base-case analysis, we assumed that H pylori treatment prevented 30% of attributable gastric cancers. FINDINGS: In the base-case analysis, 11,646,000 persons in the US would be screened and 4,658,400 treated, at a cost of $996 million. Cost-effectiveness was $25,000 per year of life saved. Cost-effectiveness was sensitive to the efficacy of the cancer prevention strategy. At low efficacy rates (< 10%), the screening programme was more expensive (> $75,000 per year of life saved). In a high-risk group such as Japanese-Americans, however, screening and treatment required less than $50,000 per year of life saved, even at 5% treatment efficacy. INTERPRETATION: Screening and treatment for H pylori infection is potentially cost-effective in the prevention of gastric cancer, particularly in high-risk populations. Cancer prevention trials are strongly recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Helicobacter pylori Infection and the Risk of Gastric Carcinoma
Parsonnet, J., Friedman, G. D., Vandersteen, D. P., Chang, Y., Vogelman, J. H., Orentreich, N., & Sibley, R. K. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110173251603 · Cited by 3,894
Self-citationMarkov Models in Medical Decision Making: A Practical Guide
Sonnenberg, F. A., & Beck, J. R. (1993) · Medical Decision Making · doi:10.1177/0272989x9301300409 · Cited by 2,419
Statistical Abstract of the United States: 2007
(2007) · Choice Reviews Online · doi:10.5860/choice.45-1769 · Cited by 2,398
Forman, D., Newell, D. G., Fullerton, F., Yarnell, J. W., Stacey, A. R., Wald, N., & Sitas, F. (1991) · BMJ · doi:10.1136/bmj.302.6788.1302 · Cited by 1,380
Helicobacter pylori in peptic ulcer disease.
van Rensburg, O. (2004) · PubMed · Cited by 1,310
Helicobacter pylori in Peptic Ulcer Disease
Yamada, T. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03520010077036 · Cited by 1,024
Epidemiology of Helicobacter pylori in an asymptomatic population in the United States
Graham, D. Y., Malaty, H. M., Evans, D. G., Evans, D. J., Klein, P. D., & Adam, E. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90644-z · Cited by 960
Prevalence of Helicobacter pylori Infection and Histologic Gastritis in Asymptomatic Persons
Dooley, C. P., Cohen, H., Fitzgibbons, P. L., Bauer, M., Appleman, M. D., Perez-Perez, G. I., & Blaser, M. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912073212302 · Cited by 760
Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population
Asaka, M., Kimura, T., Kudo, M., Takeda, H., Mitani, S., Miyazaki, T., Miki, K., & Graham, D. Y. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90156-s · Cited by 625
The incidence of Helicobacter pylori infection.
Parsonnet, J. (1995) · PubMed · Cited by 383
Self-citation
Cited by
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
Malfertheiner, P., Megraud, F., O'Morain, C., Bazzoli, F., El-Omar, E., Graham, D., Hunt, R., Rokkas, T., Vakil, N., Kuipers, E. J., et al. (2007) · Gut · doi:10.1136/gut.2006.101634 · Cited by 2,240
Cancer burden in the year 2000. The global picture
Parkin, D. M., Bray, F. I., & Devesa, S. S. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00267-2 · Cited by 2,169
Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report
Malfertheiner, P., Megraud, F., Rokkas, T., Gisbert, J. P., Liou, J.-M., Schulz, C., Gasbarrini, A., Hunt, R. H., Leja, M., O'Morain, C., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327745 · Cited by 1,533
Malfertheiner, P., Mégraud, F., O'Morain, C., Hungin, A. P. S., Jones, R., Axon, A., Graham, D. Y., Tytgat, G., & The European Helicobacter Pylori Study Group (EHPSG) (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01169.x · Cited by 1,237
Metadata
- Authors
- Parsonnet, J., Harris, R. A., Hack, H. M., & Owens, D. K.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1996-07
- Volume
- 348
- Issue
- 9021
- Pages
- 150-154
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2163581846
- Cited by
- 333
- References
- 19
- FWCI
- 27.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. https://app.cochat.ai/papers/10.1016/s0140-6736(96)01501-2
- The paper
- Parsonnet, J., Harris, R. A., Hack, H. M., & Owens, D. K. (1996). Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. The Lancet. https://doi.org/10.1016/s0140-6736(96)01501-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.